PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1
    63.
    发明申请
    PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 审中-公开
    药物,化合物和方法在通过抑制CYP17A1和CYP19A1治疗癌症中的应用

    公开(公告)号:WO2017070718A4

    公开(公告)日:2017-06-15

    申请号:PCT/ZA2016050041

    申请日:2016-10-22

    摘要: The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compounds have the formula: [Chem. 1] wherein: R is independently selected from the group consisting of optionally substituted arylamide; optionally substituted alkylarylamide; optionally substituted aryl carboxamide; optionally substituted cyanopiperidine; optionally substituted oxopiperidine; optionally substituted N-(pyridin-3-yl); optionally substituted pyridin-3-yl; optionally substituted pyrazole-4-carboxamide; optionally substituted pyrimidin-4-ylcarboxamide; optionally substituted pyrimidin-4-ylcarboxamide; optionally substituted 1H-pyrrol-2-ylcarboxamide; optionally substituted morpholin carboxamide; optionally substituted 1H-indazol-3-ylcarboxamide; optionally substituted 5-cyanopiperidin-3-ylcarboxamide; optionally substituted quinolin-7-yl; optionally substituted pyrazin-2-ylcarboxamide; optionally substituted 1H-1,3-benzodiazole-6-carboxamide; and optionally substituted 3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-ylcarboxamide; Each R1, R2, R3, R4, R5 is independently selected from the group consisting of H; OH; a halogen atom; OCH3; and NH2; and X is independently selected from the group consisting of O, H and OH. Some of the compounds are claimed per se and the invention also encompasses pharmaceutically acceptable salts, solvates, hydrates, primary metabolites and prodrugs thereof.

    摘要翻译: 本发明提供了用作药物的化合物,其通过抑制CYP17A1和CYP19A1酶起作用。 这些化合物特别用于治疗癌症,特别是前列腺癌和乳腺癌。 该化合物具有下式:[化学式 1]其中:R独立地选自任选取代的芳基酰胺; 任选取代的烷基芳基酰胺; 任选取代的芳基甲酰胺; 任选取代的氰基哌啶; 任选取代的氧代哌啶; 任选取代的N-(吡啶-3-基); 任选取代的吡啶-3-基; 任选取代的吡唑-4-甲酰胺; 任选取代的嘧啶-4-基甲酰胺; 任选取代的嘧啶-4-基甲酰胺; 任选取代的1H-吡咯-2-基甲酰胺; 任选取代的吗啉甲酰胺; 任选取代的1H-吲唑-3-基甲酰胺; 任选取代的5-氰基哌啶-3-基甲酰胺; 任选取代的喹啉-7-基; 任选取代的吡嗪-2-基甲酰胺; 任选取代的1H-1,3-苯并二唑-6-甲酰胺; 和任选取代的3-氧代-3,4-二氢-2H-1,4-苯并恶嗪-7-基甲酰胺; 每个R 1,R 2,R 3,R 4,R 5独立地选自H; 哦; 卤素原子; OCH 3; 和NH 2; X独立地选自O,H和OH。 某些化合物本身是要求保护的,本发明还包括其药学上可接受的盐,溶剂合物,水合物,初级代谢产物和前药。

    POLYAMINE SULFONAMIDES AND USES THEREOF
    65.
    发明申请
    POLYAMINE SULFONAMIDES AND USES THEREOF 审中-公开
    多胺磺酰胺及其用途

    公开(公告)号:WO2017079609A1

    公开(公告)日:2017-05-11

    申请号:PCT/US2016/060598

    申请日:2016-11-04

    IPC分类号: C07C311/05 A61K31/18

    摘要: Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases ( e.g ., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.

    摘要翻译: 癌症是一种仍然存在很大未满足的医疗需求的疾病,因此发现和开发新的抗肿瘤药物是至关重要的。 本发明部分涉及具有抗肿瘤活性的新型治疗化合物。 本文提供的是聚胺磺酰胺,例如式(I)化合物或其药学上可接受的盐,其可用于治疗和/或预防诸如癌症的疾病。 本文还提供了包含本发明化合物的药物组合物和试剂盒。 此外,本发明提供使用式(I)化合物或其药学上可接受的盐或其药物组合物治疗和/或预防疾病(例如癌症)的方法。 提供的其他方法包括诱导细胞凋亡的方法,以及体内和体外抑制α-烯醇酶酶活性的方法。

    急性腎障害の予防または抑制用医薬
    66.
    发明申请
    急性腎障害の予防または抑制用医薬 审中-公开
    用于预防或抑制急性KIDNEY伤害的药物药物

    公开(公告)号:WO2017061461A1

    公开(公告)日:2017-04-13

    申请号:PCT/JP2016/079606

    申请日:2016-10-05

    摘要: 本発明は、急性腎障害を予防又は抑制するための新規な医薬として、アンジオテンシン2型受容体アゴニスト又はその薬理的に許容される塩を有効成分として含有する、急性腎障害を治療又は予防するための医薬を提供する。 また、本発明は、急性腎障害を予防又は抑制するための新規な方法として、抗癌剤及び/又は抗腫瘍剤と組み合わせて、アンジオテンシン2型受容体アゴニスト又はその薬理的に許容される塩の有効量を患者に投与することを含む、急性腎障害の予防または抑制方法を提供する。

    摘要翻译: 本发明提供一种用于预防或抑制急性肾损伤的新型药物,含有血管紧张素II受体拮抗剂或其药理学上可接受的盐作为活性成分的药物,用于治疗或预防急性肾损伤。 还提供了一种用于预防或抑制急性肾损伤的新方法,包括与抗癌剂和/或抗肿瘤剂组合,向患者施用有效剂量的血管紧张素II受体拮抗剂或其药理学上可接受的盐。